The Distinction of the Interactions Between the Transmembrane Domains of Basigin Gene Products and Monocarboxylate Transporters by Fong, Joseph D
UNF Digital Commons
UNF Graduate Theses and Dissertations Student Scholarship
2018
The Distinction of the Interactions Between the
Transmembrane Domains of Basigin Gene
Products and Monocarboxylate Transporters
Joseph D. Fong
University of North Florida
This Master's Thesis is brought to you for free and open access by the
Student Scholarship at UNF Digital Commons. It has been accepted for
inclusion in UNF Graduate Theses and Dissertations by an authorized
administrator of UNF Digital Commons. For more information, please
contact Digital Projects.
© 2018 All Rights Reserved
Suggested Citation
Fong, Joseph D., "The Distinction of the Interactions Between the Transmembrane Domains of Basigin Gene Products and






THE DISTINCTION OF THE INTERACTIONS BETWEEN THE TRANSMEMBRANE 
DOMAINS OF BASIGIN GENE PRODUCTS AND MONOCARBOXYLATE 
TRANSPORTERS  
By 
Joseph D. Fong 
 
A thesis submitted to the Department of Biology 
 in partial fulfillment of the requirements for the degree of  
Master of Science in Biology  
UNIVERSITY OF NORTH FLORIDA 









The thesis of Joseph D. Fong is approved:      Date 
__________________________________      ___________ 
Judith D. Ochrietor 
 
__________________________________      ___________ 
Jim Gelsleichter 
 




Accepted for the Biology Department: 
 
_________________________________      ___________ 
Cliff Ross, Chair 
 
 
Accepted for the College of Arts and Sciences: 
 
_________________________________      ___________ 
George Rainbolt, Dean 
 
 
Accepted for the University: 
 
_________________________________      ___________ 






• Drs. J. Gelsleichter and E. Stotz-Potter, my graduate committee, for providing their time 
and assistance graciously throughout the pursuit of my Master of Science Degree. 
• Megan Fong, my wife, whose love and encouragement have helped me stay grounded 
and keep moving through all the roadblocks and setbacks. 
• My family, for their limitless love and support in all my endeavors. 
• My friends, for the long hours spent in commiseration on our journeys. 
• My fellow students in Dr. Ochrietor’s laboratory and the Biology department who 
understand the hard work and frustrations required for a Master of Science degree. 
• Dr. J. D. Ochrietor, whose encouragement and guidance have left me with a debt I can 











Table of Contents 
 
Acknowledgments ……………………………………………………………………………iii 
Table of Contents …………………………………………………………………………….iv 
List of Figures and Tables ……………………………………………………………………v   
Abstract ………………………………………………………………………………………ix 
Chapter 1: Introduction ………………………………………………………………………1 
Chapter 2: Materials and Methods …………………………………………………………...17 
Chapter 3: Results ……………………………………………………………………………22 





















































The four classes of cell adhesion molecules.  These include the 
immunoglobulin (Ig) superfamily, cadherins, selectins, and integrins. 
(Alberts et al., 2000) 
 
Comparison of the structures of Neuroplastin, Basigin, and Embigin.  
Each protein family possesses extracellular Ig domains, a 
transmembrane domain, and a cytoplasmic domain.  All members of 
this subset of the IgSF possess a glutamate (E) within the 
transmembrane domain.  There are two Basigin and Neuroplastin gene 
products.  The longer product is depicted by the additional lighter 
colored domain at the region most distal from the membrane. (Beesley 
et al., 2014) 
 
Structure of monocarboxylate transporters.  The overall structure is 
depicted using circles that represent each amino acid in the protein.  
The circles are color-coded to indicate the class of amino acid present 
at each position.  MCTs possess ten to twelve transmembrane 
domains, with a large cytoplasmic domain between transmembrane 
domains six and seven.  Both the amino- and carboxy-termini are 
positioned within the cell.  (Halestrap and Price, 1999) 
 
Amino acid sequence comparison of MCT1, MCT2, and MCT4.  The 
one-letter amino acid code is shown for each transporter.  Positions 
that share identical amino acids are noted with an asterisk (*), whereas 
positions that have conserved substitutions are noted with a colon (:) 
or a period (.), depending on the strength of the conservation.  The 
boxed sequence shows transmembrane domain 3, the region of MCT1 
thought to interact with Basigin. 
 
The astrocyte-neuron coupling mechanism proposed to exist in the 
mammalian brain.  Glucose is taken up by astrocytes and metabolized 
to lactate, which is then delivered to neurons and used as a substrate 



































































































The entire transmembrane domain of Basigin gene products (BasTM-
All) is shown using the amino acid one-letter code.  It was determined 
by Finch et al., (2009), that the transmembrane domain of Basigin 
gene products (BasTM) binds to MCT1 using the hydrophobic amino 
acids shown in blue.  One letter code: A = alanine; E = glutamate; F = 
phenylalanine; G = glycine; I = isoleucine; L = leucine; M = 
methionine; P = proline; T = threonine; V = valine; W = tryptophan; Y 
= tyrosine. 
 
Basigin gene products affect the expression of MCT1 and MCT4, but 
not MCT2 in the mouse neural retina.  An immunoblot of neural retina 
membrane-associated protein expression is shown.  Samples from 
Basigin normal (Bsg +/+) and null (Bsg -/-) were tested from animals 
at 20-days of age and one year of age.  In the top panels, the proteins 
were probed with an antibody specific for the glutamate transporter 
GLUT1, which served as a loading control.  The remaining panels 
show the results of probing with antibodies specific for MCT1, 
MCT4, and MCT2. Expression of MCT1 and MCT4 is reduced in the 
null animals, as compared to the age-matched normal animals, 
whereas the expression of MCT2 is similar for all samples. (Philp et 
al., 2003). 
 
Binding of Bas-TM-all to MCTs.  The ability of Bas-TM-all to bind to 
MCT1 (A), MCT2 (B), and MCT4 (C) was assessed via an in vitro 
binding assay.  In all cases, the binding of BasTM-all was 
significantly greater than that of the vector control protein (Control).    
 
Binding curves for BasTM-6xHis with MCT1, MCT2, and MCT4.  
For each transporter, the absorbance obtained for 10 M was set to 
100% binding, and the other absorbances were compared to it.  A 
logarithmic trendline was applied and the equation was used to 
determine the affinity.  The R2 value for each trendline is shown. 
 
Binding affinity of BasTM-6xHis for MCT1, MCT2, and MCT4 in 
µM. 
 
Binding of BasTM truncation mutants to MCT2.  The ability of each 
section of the transmembrane domain of Basigin (BasTM 1-6, BasTM 
7-12, BasTM 13-18, BasTM 19-24) to bind to MCT2 was assessed 
through an in vitro binding assay.  The binding of each BasTM protein 
was individually compared to that of the control protein using a 

































































































Binding affinity of BasTM-all and the Bas-TM truncation mutants for 
MCT2 in M.  The p-value was obtained via a paired, one-tailed T-
test comparing each mutant to the BasTM-all protein. 
 
Binding curve of BasTM-all-E13G for MCT2.  The absorbance 
obtained for 10 M was set to 100% binding, and the other 
absorbances were compared to it.  A logarithmic trendline was applied 
and the equation was used to determine the affinity.  The R2 value for 
the trendline is shown. 
 
Binding of BasTM 1-6 mutants to MCT2.  The ability of each amino 
acid to contribute to binding to MCT2 was evaluated through an in 
vitro binding assay, and compared to that of the BasTM 1-6 sequence, 
which was set to 100% binding.  Mutants with binding greater than 
100% are thought to inhibit the interaction with MCT2, whereas those 
with binding less than 100% are thought to be involved in the 
interaction.  *=p<0.05 when individually compared to BasTM 1-6 via 
a paired, one-tailed T-test. 
 
Binding of BasTM 7-12 mutants to MCT2.  The ability of each amino 
acid to contribute to binding to MCT2 was evaluated through an in 
vitro binding assay, and compared to that of the BasTM 7-12 
sequence, which was set to 100% binding.  Mutants with binding 
greater than 100% are thought to inhibit the interaction with MCT2, 
whereas those with binding less than 100% are thought to be involved 
in the interaction.  *=p<0.05 when individually compared to BasTM 
7-12 using a paired, one-tailed T-test. 
 
Binding of BasTM truncation mutants to MCT4. The ability of each 
section of the transmembrane domain of Basigin (BasTM 1-6, BasTM 
7-12, BasTM 13-18, BasTM 19-24) to bind to MCT4 was assessed 
through an in vitro binding assay.  The binding of each BasTM mutant 
protein was individually compared to that of the BasTM-all protein 
using a paired, one-tailed T-test.  The asterisk (*) represents p=<0.01. 
 
Binding affinity of BasTM-all and the Bas-TM truncation mutants for 
MCT4 in M.  The p-value was obtained via a paired, one-tailed T-
test comparing each mutant to the BasTM-all protein. 
 
Binding curve of BasTM-all-E13G for MCT4. The absorbance 
obtained for 10 M was set to 100% binding, and the other 
absorbances were compared to it.  A logarithmic trendline was applied 
and the equation was used to determine the affinity.  The R2 value for 























































































Binding of BasTM 1-6 mutants to MCT4. The ability of each amino 
acid to contribute to binding to MCT4 was evaluated through an in 
vitro binding assay, and compared to that of the BasTM 1-6 sequence, 
which was set to 100% binding.  Mutants with binding greater than 
100% are thought to inhibit the interaction with MCT4, whereas those 
with binding less than 100% are thought to be involved in the 
interaction.  *=p<0.05 when individually compared to BasTM 1-6 
using a paired, one-tailed T-test. 
 
Binding of BasTM 13-18 mutants to MCT4.  The ability of each 
amino acid to contribute to binding to MCT4 was evaluated through 
an in vitro binding assay, and compared to that of the BasTM 13-18 
sequence, which was set to 100% binding.  Mutants with binding 
greater than 100% are thought to inhibit the interaction with MCT4, 
whereas those with binding less than 100% are thought to be involved 
in the interaction.  *=p<0.05 when individually compared to BasTM 
13-18 using a paired, one-tailed T-test. 
 
Expression of Basigin and MCT2 in the mouse retina.  In both panels, 
the green fluorescence represents protein expression (Basigin or 
MCT2) and the blue fluorescence represents DRAQ5, which binds 
DNA.  The magnification bar represents 50 m.  Abbreviations: RPE, 
retinal pigmented epithelium; ONL, outer nuclear layer; OPL, outer 
plexiform layer; INL, inner nuclear layer; IPL, inner plexiform layer. 
 
Expression of Basigin and MCT2 in mouse tongue.  In the left panel, 
Basigin expression is represented by red fluorescence.  In the right 
panel, MCT2 expression is represented by green fluorescence.  In both 
panels, DRAQ 5 binding to DNA is represented by the blue 
fluorescence.  The magnification bars represent 50 m. 
 
Summary of Basigin binding to monocarboxylate transporters.  The 
transmembrane domain is depicted with the one-letter code for the 
individual amino acids shown in the circles.  Amino acids within 
white circles are not used to bind any MCT.  Amino acids within blue 
circles are used by MCT1 only.  Amino acids within red circles are 
used by MCT4 only.  Amino acids within green circles are used by 
MCT1 and MCT2.  Amino acids within yellow circles are used by 
























































Although it was once thought that neurons solely rely on glucose as a substrate for 
cellular energy production, it is now known that small monocarboxylate molecules, like 
pyruvate, lactate, and ketone bodies, are also utilized.  Monocarboxylates are transported across 
plasma membranes via facilitated diffusion using a family of transport proteins known as 
monocarboxylate transporters (MCTs).  Four MCTs (MCT1, MCT2, MCT3, and MCT4) are 
expressed within neural tissues.  Expression of the MCTs has been tied to co-expression of a cell 
adhesion molecule belonging to the Basigin subset of the immunoglobulin superfamily (IgSF).  
Basigin gene products are known to interact with MCT1 and MCT4 in the mammalian neural 
retina and this association is essential to support the cellular energy needs of photoreceptors.  A 
previous study indicated that Basigin gene products use hydrophobic amino acids within specific 
regions of the transmembrane domain to interact with MCT1.  In the present study, it is 
hypothesized that the same amino acids within the transmembrane domain are used to interact 
with MCT4, but that no association exists with MCT2, which typically interacts with a different 
member of the IgSF subset.  Therefore, the purpose of the present study was to assess the 
association between Basigin gene products and MCT4, and with MCT2.  Recombinant proteins 
corresponding to the transmembrane domain of Basigin gene products were used in in vitro 
binding assays with endogenous MCT2 and MCT4 from mouse brain protein lysates.  Contrary 
to the hypothesis, it was determined that the transmembrane domain of Basigin gene products 
binds to both MCT2 and MCT4 in vitro.  Different amino acids within the transmembrane 
domain of Basigin gene products are used for each association and the pattern is different from 







Cell adhesion is an essential process for the maintenance and development of tissues, 
synaptogenesis, and embryonic development. Connections between cells, mediated by cell-
surface proteins, underlie all these processes, and set up the three-dimensional structure of 
tissues (Gumbiner, 1996).  The proteins involved in cell adhesion can be classified into one of 
four classes of cell adhesion molecules (Figure 1.1), which include the immunoglobulin 
superfamily (IgSF), cadherins, selectins, and integrins (Alberts et al., 2015). Studies of the 
expression, structure, and function of cell adhesion molecules are powerful ways to understand 
the molecular composition of a tissue, and hence its function.   
 
Immunoglobulin Super Family 
The IgSF is the largest group of four types of cell adhesion molecules (Beesley et al., 
2014; Alberts et al., 2015).  Members of the IgSF are typically characterized by a large amino-
terminal extracellular domain containing one or more Ig folds, a single transmembrane domain, 
and a cytoplasmic tail (Aplin et al., 1998).  These Ig folds are similar in structure to those found 
in immunoglobulins, or antibodies, and therefore provide the commonality for this group of 
proteins (Alberts et al., 2015).  IgSF cell adhesion molecules are involved in many processes and 







Figure 1.1.  The four classes of cell adhesion molecules.  These include the immunoglobulin (Ig) 





used in the establishment and maintenance of neuronal connections and axonal guidance (Murase 
and Schuman, 1999). 
 
Cadherins 
Cadherins are a family of transmembrane proteins that possess an extracellular domain 
with a series of repeats of 100-amino acid cadherin-specific modules (Juliano, 2002).  The 
cadherin family of cell adhesion molecules can be divided into three major subfamilies.  The first 
subfamily is composed of primarily calcium-dependent homotypic cell adhesion molecules 
referred to as “classic” cadherins.  This subset of cadherins specializes in the formation of 
adherence junctions with actin filaments (Angst et al., 2001).  The second subfamily is composed 
of desmosome-associated cell adhesion molecules.  These cadherins form intracellular linkages 
with intermediate filaments, rather than actin filaments (Hynes, 1999).  The final subfamily of 
cadherins are the proto-cadherins.  These are important for the development of the nervous 
system (Angst et al, 2001).  
 
Selectins 
The selectin family of cell adhesion molecules consist of a small family of lectin-like 
adhesion receptors (Lasky, 1995).  Lectins are carbohydrate-binding proteins (Aplin et al., 1998).  
Selectins possess an amino-terminal domain homologous to calcium-dependent animal lectins, 
an epidermal growth factor domain, two to nine complement regulatory protein repeats, a 
transmembrane domain, and a short cytoplasmic tail (Juliano, 2002). Selectins regulate 
heterotypic cell interactions via calcium-dependent recognition of sialylated glycans, which 
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plays a role in leukocyte adherence to endothelial cells and platelets during the inflammation 
process (Springer, 1995).  
 
Integrins 
Integrins are cell-surface glycoproteins that serve as receptors for extracellular matrix 
proteins and connect to the cytoskeleton, hence “integrating” the outside of the cell with the 
inside of the cell (Juliano, 2002). Integrins exist as heterodimers consisting of two subunits, 
known as α and β.  The  and  subunits each contain an extracellular domain, a membrane 
spanning region, and cytoplasmic domain (Hynes, 1999; Aplin et al., 1998).  Signals originating 
outside the cell are responsible for cytoskeletal organization, cell motility, and signal 
transduction, whereas signals originating from inside the cell are responsible for regulation of 
integrin affinity (Juliano, 2002). 
 
Basigin subset of the IgSF 
Within the IgSF exists a subset of proteins that includes two Basigin gene products, two 
Neuroplastin gene products, and Embigin.  These five proteins are classified as a subset of the 
IgSF based on the similarities of these proteins at the amino acid level, and therefore their 
structures (Beesley et al., 2014).  As members of the IgSF, they share a similar structure, with 
extracellular Ig-like domains, a transmembrane domain, and a cytoplasmic domain (Figure 1.2; 
Beesley et al., 2014).  A defining feature of this subset of the IgSF is the presence of a glutamate 
residue within the transmembrane domain (Beesley et al., 2014).  The function of this polar 





Figure 1.2.  Comparison of the structures of Neuroplastin, Basigin, and Embigin.  Each protein 
family possesses extracellular Ig domains, a transmembrane domain, and a cytoplasmic domain.  
All members of this subset of the IgSF possess a glutamate (E) within the transmembrane domain.  
There are two Basigin and Neuroplastin gene products.  The longer product is depicted by the 





for Basigin and the gene for Neuroplastin each produce two main protein products that differ in 
overall size.  The shorter forms of Basigin (Basigin variant-2) and Neuroplastin (Neuroplastin 
gp55) are ubiquitously expressed and each have two extracellular Ig domains (Beesley et al., 
2014). The longer forms of Basigin (Basigin variant-1) and Neuroplastin (Neuroplastin gp65) are 
expressed in the retina and the brain, respectively, and have three extracellular Ig domains each 
(Figure 1.2; Beesley et al., 2014). The Embigin gene is unique to this subset, in that it codes for a 
single polypeptide that has two extracellular Ig domains (Figure 1.2; Beesley et al., 2014).  
Embigin is known as the “embryonic Ig,” based on early studies that indicated that expression is 
highest during embryonic development (Fan et al., 1998).  More recently, it has been determined 
to be expressed during tissue regression of rat prostate and in mammary glands following 
hormonal ablation (Guenette et al., 1997), as well as in adult rodent muscle (Lain et al., 2009).  
As cell adhesion molecules, members of the Basigin subset of the IgSF play many roles 
in many different tissues.  Basigin variant-2 is known to be involved in glial cell maturation, 
oocyte maturation, thymic development, and HIV-1 infection (Ding et al., 2002; Renno et al., 
2002; Pushkarsky et al., 2001).  Conversely, Basigin variant-1 is expressed only in the neural 
retina and is thought to play a role in regulation of glucose metabolism (Ochrietor et al., 2003; 
Ait-Ali et al., 2015).  The Neuroplastin gene products are specific to the brain and nervous 
system and are important for mediating neurite outgrowth and plasticity, especially activity-
dependent synaptic plasticity (Beesley et al., 2014).  Whereas Neuroplastin gp55 is expressed 
throughout the mammalian brain, Neuroplastin gp65 expression is predominantly found in the 
hippocampus, cortex, and striatum, with lower concentrations in the brainstem (Hill et al., 1988; 
Mlinac et al., 2012.; Smalla et al., 2000; Marzban et al., 2003).  Embigin regulates cell growth 
and differentiation during embryonic development (Guenette et al., 1997).  Embigin mRNA 
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levels are elevated in embryonic carcinoma cells, which supports the hypothesis that it is 
involved in tumorigenesis and cancer development as well (Huang et al., 1990).  The common 
feature of the Basigin subset of the IgSF is their ability to associate with, and direct the 
expression of, monocarboxylate transporters (Beesley et al., 2014). 
 
Monocarboxylate Transporters 
  Monocarboxylate transporters (MCTs) are members of the MCT solute carrier family of 
proteins.  All family members possess a similar characteristic structure, consisting of twelve 
transmembrane helices with intracellular carboxy- and amino-termini, as well as a large cytosolic 
loop between transmembrane domains six and seven (Figure 1.3; Halestrap and Price, 1999). 
There are nine different MCT isoforms, but only four of these (MCT1, MCT2, MCT3 and 
MCT4) are known to transport pyruvate, lactate, and ketone bodies (monocarboxylates) via 
facilitated diffusion, in a proton-dependent manner (Halestrap and Price, 1999).  These isoforms 
are known to interact with members of the Basigin subset of the IgSF and will therefore be the 
focus of this discussion. However, because MCT3 is retina-specific (Philp et al., 2001), for this 
discussion the focus will be on MCT1, MCT2, and MCT4. A comparison of the amino acid 
sequences of MCT1, MCT2, and MCT4 is shown in Figure 1.4.  The area designated by the box 
shows transmembrane domain 3, which is thought to be the region within MCT1 that interacts 












Figure 1.3. Structure of monocarboxylate transporters.  The overall structure is depicted 
using circles that represent each amino acid in the protein.  The circles are color-coded to indicate 
the class of amino acid present at each position.  MCTs possess ten to twelve transmembrane 
domains, with a large cytoplasmic domain between transmembrane domains six and seven.  Both 









Figure 1.4. Amino acid sequence comparison of MCT1, MCT2, and MCT4.  The one-letter amino 
acid code is shown for each transporter.  Positions that share identical amino acids are noted with 
an asterisk (*), whereas positions that have conserved substitutions are noted with a colon (:) or a 
period (.), depending on the strength of the conservation.  The boxed sequence shows 
transmembrane domain 3, the region of MCT1 thought to interact with Basigin. 
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The MCT family members are expressed throughout the body.  MCT1 is expressed in 
many tissues and is thought to be responsible for basal monocarboxylate transport across 
epithelial membranes (Halestrap, 2012).  Within the brain, MCT1 and MCT2 expression has 
been localized to the neocortex, hippocampus, cerebellum, and striatum (Pellerin et al., 1998).  In 
areas where MCT1 and MCT2 are both expressed, they are differentially localized, which may 
be due to unique functional roles for each transporter (Halestrap, 2012).   Expression of MCT2 is 
largely found in the postsynaptic density of neurons and may therefore facilitate the uptake of 
monocarboxylates for those cells (Halestrap, 2012).  Conversely, expression of MCT1 is largely 
found in the heart, brain, and retina (Bergersen, 2007; Halestrap and Price, 1999). MCT1 is 
particularly expressed in the endothelial cells of capillaries in the brain (Bergersen, 2007). MCT4 
is widely expressed in glycolytic tissues, such as white skeletal muscle fibers, astrocytes, white 
blood cells, chondrocytes, and some mammalian cell lines.  It is thought that MCT4 may be 
involved in the export of lactic acid derived from glycolysis (Halestrap, 2012). While highly 
glycolytic cells are shown to predominantly express and utilize MCT4, cells that have a net 
influx of lactic acid express and utilize predominantly MCT1 (Kirk et al., 2000).  MCT3 is 
unique to this group in that its expression is restricted to the retinal pigmented epithelium (RPE) 
of the eye (Philp et al., 2001).  Excess lactate from the neural retina is moved into the RPE via 
apically-expressed MCT1 and out of the RPE toward the choroid via basally-expressed MCT3 
(Philp et al., 2001).   
The mechanism by which MCTs transport monocarboxylates has been studied in detail 
using inhibitors, transport kinetics, and site-directed mutagenesis (Halestrap, 2012). The MCT1 
transporter has been the prototype molecule used for many of these studies.  The mechanism 
MCT1 utilizes is one in which a substrate binding site, open to one side of the membrane, binds a 
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proton and lactate anion, causing a conformational change in the protein which brings the two to 
the opposite surface of the membrane (Halestrap, 2012). The MCT1 transporter specifically uses 
a lysine residue in the hydrophobic pocket of the substrate-binding channel, that when coupled 
with the binding of a proton, allows for the binding of the monocarboxylate anion (Halestrap, 
2012).  
While glucose is considered the main energy source for the brain, lactate and ketone 
bodies can be utilized by neurons within the brain (Koehler-Stec et al., 1998).  It has been 
proposed that neurons obtain these metabolites to fuel oxidative phosphorylation using an 
astrocyte-neuron coupling mechanism (Figure 1.5; Magistretti, 2006).  It is thought that glucose 
is taken up by astrocytes (glial cells), using the GLUT-1 transport protein (Magistretti, 2006), 
and converted to pyruvate via glycolysis.  The pyruvate is then reduced to lactate and shuttled to 
neurons in close association with the astrocyte, which oxidize lactate to pyruvate and continue 
the process of aerobic respiration (Magistretti, 2006).  Lactate converted to ketone bodies within 
the liver and released into the bloodstream can also be used by neurons, upon conversion of the 
ketone bodies to pyruvate (Koehler-Stec et al., 1998).  In addition, glucose directly enters the 
neurons, via a separate mechanism, for glycolysis and aerobic respiration in those cells 
(Magistretti, 2006).  Not shown in the diagram are the MCTs that contribute to lactate transport 











Figure 1.5. The astrocyte-neuron coupling mechanism proposed to exist in the mammalian brain.  
Glucose is taken up by astrocytes and metabolized to lactate, which is then delivered to neurons 




The relationship between members of the Basigin subset of the IgSF and MCTs 
Numerous studies conducted over the past two decades indicate that MCTs associate with 
members of the Basigin subset of the IgSF.  Basigin gene products are known to associate with 
MCT1 and MCT4, as demonstrated via in vitro and in vivo analyses (Kirk et al., 2000; Wilson et 
al., 2002; Philp et al., 2003; Finch et al., 2009).  It has been proposed that expression of MCT1 is 
dependent of its association with Basigin gene products, because absence of Basigin gene 
expression in a mouse model system results in the absence of MCT1 protein at the plasma 
membrane of the cell (Philp et al., 2003).  The co-expression of Basigin and MCT1 correlates 
with a substantially enhanced rate of lactate transport, as compared to cells not expressing both 
proteins (Kirk et al., 2000).  Similarly, a recent study suggests that Neuroplastin gene products 
associate with MCT2 on neurons, although a direct relationship was not established (Wilson et 
al., 2013).  In another study, Embigin was co-expressed with MCT1 in erythrocytes (Wilson et 
al., 2009).  Although the study was limited by heterologous expression, rather than endogenous 
expression, it did demonstrate that the two proteins interact at the plasma membrane (Wilson et 
al., 2009).   
The interaction between Basigin gene products and MCT1 has been studied at the 
molecular level.  Binding studies utilizing recombinant forms of the transmembrane domain of 
Basigin gene products and endogenous mouse neural retina MCT1 demonstrated that this domain 
of Basigin gene products does bind to MCT1 (Finch et al., 2009).  Although it was hypothesized 
that the central glutamate within the domain would play a significant role in binding to MCT1 
(Wilson et al., 2002), it did not appear to play any role in the interaction (Finch et al., 2009).  In 
contrast, hydrophobic interactions were found to be responsible for the interaction with MCT1 










Figure 1.6.  The entire transmembrane domain of Basigin gene products (BasTM-All) is shown 
using the amino acid one-letter code.  It was determined by Finch et al., (2009), that the 
transmembrane domain of Basigin gene products (BasTM) binds to MCT1 using the hydrophobic 
amino acids shown in blue.  One letter code: A = alanine; E = glutamate; F = phenylalanine; G = 
glycine; I = isoleucine; L = leucine; M = methionine; P = proline; T = threonine; V = valine; W = 









In a study using a mouse model system, it was determined that Basigin gene expression 
affects the expression of MCT1 and MCT4, but not MCT2 (Figure 1.7; Philp et al., 2003).  
Immunoblotting analyses using detergent-solubilized protein lysates of the neural retinas from 
Basigin null and control animals indicated that expression of MCT1 and MCT4 proteins was 
significantly reduced at the plasma membrane of Basigin null animals, as compared to the 
control animals (Figure 1.7; Philp et al., 2003).  In contrast, the expression of MCT2 protein was 
not different between the two groups (Figure 1.7; Philp et al., 2003).  It is known that Basigin 
gene products interact with MCT1 via the transmembrane domain (Finch et al., 2009).  
Therefore, the purpose of the present study was to determine if Basigin gene products interact 
with other members of the MCT family, specifically MCT2 and MCT4, using the same 
mechanism.  Based on previous data, it was hypothesized that Basigin gene products interact 
with MCT4 in a similar manner to that of MCT1, whereas Basigin gene products do not interact 
with MCT2 and thus it will serve as a negative control.  This hypothesis was tested using a series 






Figure 1.7. Basigin gene products affect the expression of MCT1 and MCT4, but not MCT2 in the 
mouse neural retina.  An immunoblot of neural retina membrane-associated protein expression is 
shown.  Samples from Basigin normal (Bsg +/+) and null (Bsg -/-) were tested from animals at 20-
days of age and one year of age.  In the top panels, the proteins were probed with an antibody 
specific for the glutamate transporter GLUT1, which served as a loading control.  The remaining 
panels show the results of probing with antibodies specific for MCT1, MCT4, and MCT2. 
Expression of MCT1 and MCT4 is reduced in the null animals, as compared to the age-matched 









Materials and Methods 
Recombinant protein expression and isolation 
 Expression plasmids containing the cDNA for the entire transmembrane domain of 
Basigin gene products, as well as those containing truncated and mutated sequences were 
previously generated (Finch et al., 2009; Brown, 2016).  A plasmid containing no insert was also 
previously generated and served as the control for binding assays (Finch et al., 2009).  The 
expression plasmid used was pET102 (Invitrogen Corporation, Carlsbad, CA), which allows 
recombinant proteins containing an epitope of six histidine residues at the carboxy-terminus to 
be expressed in bacteria.  The plasmid codes for 157 amino acids, which mask the hydrophobic 
nature of the Basigin-specific amino acids and allows a soluble protein to be expressed. 
Recombinant protein expression was carried out by transforming BL21 cells (Invitrogen 
Corporation).  The cells were grown to mid-log phase, induced with 1 mM 
isopropylthiogalactoside (IPTG; Thermo Fisher Scientific, Hampton, NH), and grown overnight 
at 37oC with shaking.   
Recombinant proteins were isolated using the His-TALON system (Clontech, Mountain 
View, CA).  Cells were pelleted by centrifugation at 3000 ×g for 15 minutes and resuspended in 
X-tractor buffer (20 mL per 1 g of cells).  The cells were lysed by incubation for 10 minutes at 
room temperature in the presence of 100 g/mL lysozyme (Clontech) and 5 U/mL DNase I 
(Clontech).  A protein lysate was formed by centrifugation at 10,000 ×g for 20 minutes.  The 
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lysate was mixed with TALON purification resin (Clontech) for 10 minutes at room temperature.  
The resin was washed by centrifugation and the via column gravity filtration.  Proteins were 
eluted from the column using elution buffer (Clontech) in 0.5 mL fractions and the presence of 
protein was analyzed at 280 nm.   
 
Mouse brain protein lysates 
 Three adult male mouse brains were obtained using an approved protocol and 
immediately washed in phosphate buffered saline (PBS).  Each brain was homogenized in 
detergent lysis buffer (0.5% SDS, 0.05 M Tris⋅HCl, pH to 8.0, plus 1 mM fresh dithiothreitol 
(DTT)) and incubated on ice for 10 minutes.  A protein lysate was generated by centrifugation at 
16,000 ×g for 10 minutes.  
 
Bradford-Coomassie protein assay 
 Protein concentration of lysates was determined using the Bradford-Coomassie protein 
assay method (Pierce/Thermo Scientific).  Concentrations of bovine serum albumin (BSA, 
Pierce/Thermo Scientific) ranging from 2.0 mg/mL to 0.1 mg/mL were generated and mixed 
with Bradford-Coomassie binding reagent.  The absorbance at 595 nm was measured and a 
standard curve (absorbance versus protein concentration) was created.  The equation from the 
best-fit trendline (usually logarithmic) was used to determine the concentration of recombinant 




ELISA Binding Assay  
Enzyme-linked immunosorbent assays (ELISA) were used as binding assays, as 
described in Finch et al., (2009).  Capture antibody (specific for MCT1, MCT2, or MCT4; 50 
ng/mL in phosphate buffered saline [PBS]; Millipore Corporation, Billerica, MA) was plated and 
incubated overnight at 4oC.  The solution was removed, and the wells were washed with PBS 
containing 0.25% Tween-20 (PBS-T).  Bovine serum albumin (BSA; Pierce/Thermo Scientific), 
diluted to 100 g/mL in PBS, was added to all wells and incubated at 37oC for 30 minutes.  The 
solution was removed, and wells were washed with PBS-T.  Mouse brain protein lysates (100 
g/mL) were added to all wells and incubated at 37oC for 30 minutes.  The solution was 
removed, and wells were washed with PBS-T.  Recombinant proteins (diluted to 100 g/mL in 
PBS) were added to individual wells in triplicate and incubated at 37oC for 30 minutes.  The 
solution was removed, and wells were washed with PBS-T.  Primary antibody specific for the 
carboxy-terminal six-histidine tag (diluted 1:1000 in PBS; BD Biosciences) was added to all 
wells and incubated at 37oC for 30 minutes.  The solution was removed, and wells were washed 
with PBS-T.  Alkaline phosphatase-conjugated goat anti-mouse secondary antibody (diluted 
1:1000 in PBS) was added to all wells and incubated at 37oC for 30 minutes.  The solution was 
removed, and wells were washed with PBS-T.  Alkaline phosphatase substrate (PNPP, 
Pierce/Thermo Scientific) was added to all wells for color development.  The reaction was 
stopped with the addition of 2N NaOH.  The absorbance at 405 nm was measured.  All runs were 
performed in triplicate, using different protein samples, and the average absorbance was plotted.  
Binding was compared for Basigin-containing recombinant proteins with that of the control 
recombinant protein via a paired, one-tailed T-test.  For the binding assays that compared the 
mutated sequence to the normal sequence, the average absorbance for the protein with the 
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normal sequence was set to 100% binding and all mutant proteins were compared.  Binding was 
compared for mutant recombinant proteins with that of the normal recombinant protein via a 
paired, one-tailed T-test. 
Affinity binding assays were performed like the simple binding assays described, with 
the exception that varying concentrations of recombinant protein (10 M, 5 M, 2.5 M, 1.25 
M, 0.625 M) were used.  All runs were performed in triplicate, using different brain protein 
samples.  The average absorbance for the protein at 10 M was set to 100% binding and the 
absorbances for the other concentrations was compared.  A binding curve was generated and the 
equation for the logarithmic trendline was used to determine the concentration equal to 50% 
binding.  This was determined to be the binding affinity.  The similarity of binding of Basigin 
transmembrane domain recombinant protein for MCT1, MCT2, and MCT4 was compared via a 
single factor ANOVA. 
 
Immunohistochemistry 
Many previous studies by this laboratory have involved the investigation of Basigin gene 
expression in the retina. It was noted in a recent study in the lab that Basigin and MCT2 
expression appears to overlap in tongue, thus providing a biologically relevant application for in 
vitro data.  Therefore, mouse tongues were isolated from adult male mice, according to an 
accepted animal use protocol.  The organs were washed in PBS and fixed by incubation for 24 
hours in 4% paraformaldehyde in PBS at room temperature.  The tissues were embedded in 
paraffin wax and 5-m sections were cut and applied to poly-L-lysine-coated glass microscope 
slides.  The retina sections were previously generated (Ochrietor et al., 2003; Tokar et al., 2017).   
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The tissue sections were rehydrated by incubating in CitriSolve (Fisher Scientific) twice, 
for 10 minutes each time, followed by 5 minutes in 100% ethanol (Fisher Scientific), then 95% 
ethanol, then 70% ethanol, and finally tris-buffered saline (TBS).  The rehydrated sections were 
solubilized in a buffer consisting of TBS with 0.1% Triton X-100 (Fisher Scientific) and 2% 
normal goat serum (Pierce/Thermo Scientific) by incubation at 4oC overnight.  The sections were 
then incubated in the presence of an antibody specific for Basigin (Ochrietor et al., 2003) or 
MCT2 (Millipore Corporation, Billerica, MA), diluted to 5 g/mL in the solubilization buffer for 
1 hour at 37oC, followed by continued incubation at 4oC overnight.  The solution was removed, 
and the sections were washed several times with TBS.  The sections were then incubated in the 
presence of Alexa488-conjugated or Alexa594-conjugated goat anti-rabbit secondary antibody 
(Pierce/Thermo Scientific) diluted 1:1000 in solubilization buffer and incubated at 37oC for 30 
minutes.  The solution was removed, and the sections were washed several times with TBS.  
DRAQ5 (Pierce/Thermo Scientific) was added to the first TBS wash at 1:1000 dilution.  
Coverslips were applied with 30% glycerol containing p-phenylenediamine (Sigma Chemical 
Company, St.  Louis, MO) and the tissues were viewed with an Olympus Fluoview F1000 












Assessing the ability of Basigin to bind to MCT2 and MCT4 
The purpose of the present study was to assess the ability of the transmembrane domain 
of Basigin gene products to interact with MCT2 and MCT4.  Previous studies indicate that 
Basigin gene products interact with MCT1 using hydrophobic amino acids within the domain 
(Finch et al., 2009).  Other studies suggest that Basigin may interact with MCT4 using a similar 
mechanism but does not likely interact with MCT2 (Philp et al., 2003).  Therefore, the ability of 
a recombinant form of the Basigin transmembrane domain to bind to endogenous mouse brain 
MCT2 and MCT4 was tested.   
Initially, simple ELISA binding assays were employed to test the ability of the 
recombinant Basigin transmembrane domain protein to bind to endogenous mouse brain MCT2 
and MCT4.  The ability of the protein to bind to endogenous mouse brain MCT1 served as the 
positive control.  As observed previously, binding of the Basigin transmembrane domain protein 
(BasTM-all) to MCT1 was significantly greater than the binding of the vector control protein 
(control) to MCT1 (Figure 3.1A; p = 0.0009).  Similarly, the ability of BasTM-all to bind to 
MCT2 (Figure 3.1B; p = 0.009) and MCT4 (Figure 3.1C; p=0.001) was significantly greater than 
binding of the control protein.   
Next, the affinity of the transmembrane domain of Basigin gene products for MCT1, 
MCT2, and MCT4 was assessed.  Standard curves in which the recombinant BasTM-all protein  
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Figure 3.1 Binding of Bas-TM-all to MCTs.  The ability of Bas-TM-all to bind to MCT1 (A), 
MCT2 (B), and MCT4 (C) was assessed via an in vitro binding assay.  In all cases, the binding of 
BasTM-all was significantly greater than that of the vector control protein (Control).   
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was tested over a range of concentrations were used to determine the concentration at 50% 
binding, which is considered the affinity.  The affinity binding curves for BasTM-all against 
MCT1, MCT2, and MCT4 are shown in Figure 3.2.  Table 3.1 shows that the affinity of the 
BasTM-all protein for each of the transporters.  The affinities of BasTM-all for MCT1, MCT2, 
and MCT4 were not significantly different from each other (p = 0.086). 
 
Assessing the ability of the Basigin transmembrane domain to bind MCT2 
To determine which amino acids within the transmembrane domain of Basigin gene 
products are used in the interactions with MCT2, deletion mutants of the domain were used.  The 
domain was fractioned into six amino acid sections and the resulting recombinant proteins were 
used for simple binding assays.  It was determined that the region containing amino acids 1-6 
had significantly greater binding to MCT2 than the control protein (p = 0.004) and similar to that 
of the BasTM-all protein (p = 0.068; Figure 3.3).  Conversely, the regions containing amino 
acids 7-12 (p = 0.421) and 19-24 (p = 0.310) were not significantly greater than the control 
protein (Figure 3.3).  The ability of the region containing amino acids 13-18 was significantly 
lower than that of the control protein (p = 0.003; Figure 3.3).  To confirm the data obtained 
through the simple binding assays, affinity assays were performed for each section of the Basigin 
transmembrane domain (Table 3.2).  The affinity for MCT2 of the region containing BasTM 1-6 
(0.714±0.391 M) was significantly greater than that of the entire domain (BasTM-all; 1.70 
±0.24 M; p = 0.041).  The affinities for MCT2 of the regions contain BasTM 13-18 (2.82±0.22 






Figure 3.2 Binding curves for BasTM-6xHis with MCT1, MCT2, and MCT4.  For each transporter, 
the absorbance obtained for 10 M was set to 100% binding, and the other absorbances were 
compared to it.  A logarithmic trendline was applied and the equation was used to determine the 









Transporter Binding affinity (M)
MCT-1 1.74 +/- 0.12
MCT-2 1.70 +/- 0.24








Figure 3.3 Binding of BasTM truncation mutants to MCT2.  The ability of each section of the 
transmembrane domain of Basigin (BasTM 1-6, BasTM 7-12, BasTM 13-18, BasTM 19-24) to 
bind to MCT2 was assessed through an in vitro binding assay.  The binding of each BasTM protein 
was individually compared to that of the control protein using a paired, one-tailed T-test.  The 







Table 3.2 Binding affinity of BasTM-all and the Bas-TM truncation mutants for MCT2 in M.  








BasTM-all 1.70 ±0.24 M
BasTM 1-6 0.714±0.391 M 0.041
BasTM 7-12 1.70±0.88 M 0.492
BasTM 13-18 2.82±0.22 M 0.019
BasTM 19-24 2.66±0.30 M 0.045
BasTM-all-E13G 1.43±0.266 M 0.187
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0.019, p = 0.045, respectively).  Contrary to the data obtained from the simple binding assay, the 
affinity for MCT2 of the region containing BasTM 7-12 (1.70±0.88 M) was the same as that for 
BasTM-all.  These data suggest that binding of the transmembrane domain of Basigin to MCT2 
employs amino acids within the first twelve residues of the domain.   
The glutamate residue found in the center of the transmembrane domain of Basigin, at 
position 13, has been hypothesized by others to be essential for the interaction with MCTs (Kirk 
et al., 2000; Wilson et al., 2002).  Although the affinity data generated through this study suggest 
otherwise, a direct assessment of the residue was performed using a recombinant version of the 
entire Basigin transmembrane domain, in which the amino acid glutamate was mutated to 
glycine (BasTM-all-E13G), and in an affinity binding assay (Figure 3.4).  The affinity of the 
BasTM-all-E13G protein for MCT2 was determined to be 1.429 ± 0.266 M, which is not 
statistically different from the affinity of the wild-type sequence for the transporter when 
compared using a paired, one-tailed T-test (p = 0.187; Table 3.2).  These data suggest that the 
glutamate plays no role in the interaction between Basigin and MCT2. 
To determine which amino acids in the segment containing amino acids 1-6 are used in 
the interaction with MCT2, deletion mutants in which individual amino acids were mutated to 
glycine were used.  Binding of each mutant was compared to that of the BasTM 1-6 protein 
(Figure 3.5).  It was determined that the proteins containing an alanine-to-glycine mutation at 
position 3 (p = 0.001) and a leucine-to-glycine at position 4 (p = 0.01) had significantly lower 
binding to MCT2 than the BasTM 1-6 protein.  These amino acids are likely used in the 
association with MCT2.  The proteins containing a methionine-to-glycine mutation at position 1 








Figure 3.4 Binding curve of BasTM-all-E13G for MCT2.  The absorbance obtained for 10 M 
was set to 100% binding, and the other absorbances were compared to it.  A logarithmic trendline 











Figure 3.5 Binding of BasTM 1-6 mutants to MCT2.  The ability of each amino acid to contribute 
to binding to MCT2 was evaluated through an in vitro binding assay, and compared to that of the 
BasTM 1-6 sequence, which was set to 100% binding.  Mutants with binding greater than 100% 
are thought to inhibit the interaction with MCT2, whereas those with binding less than 100% are 
thought to be involved in the interaction.  *=p<0.05 when individually compared to BasTM 1-6 





mutation at position 5 (p = 0.05) had significantly greater binding to MCT2 than the BasTM 1-6 
protein.  These amino acids likely inhibit the interaction with MCT2. 
To determine which amino acids in the segment containing amino acids 7-12 are used in 
the interaction with MCT2, deletion mutants in which individual amino acids were mutated to 
glycine were used.  Binding of each mutant was compared to that of the BasTM 7-12 protein 
(Figure 3.6).  It was determined that mutation of no amino acids resulted in a significant decrease 
in binding.  On the contrary, mutation of the phenylalanine at position 7 (p=0.003), the leucine at 
position 8 (p=0.006), the isoleucine at position 10 (p=0.031), and the alanine at position 12 
(p=0.009) had significantly greater binding to MCT2 than BasTM 7-12.  Mutation of the valine 
at position 11 had similar binding to MCT2 as BasTM 7-12 (p=0.247).  The amino acid at 
position 9 is glycine and therefore was not mutated. 
 
Assessing the ability of the Basigin transmembrane domain to bind MCT4 
To determine which amino acids within the transmembrane domain of Basigin gene 
products are used in the interactions with MCT4, deletion mutants of the domain were again 
used.  It was determined that the regions containing amino acids 1-6 and 7-12 had significantly 
greater binding to MCT4 than the control protein (p = 0.018, 0.024, respectively; Figure 3.7) and 
similar to that of the BasTM-all protein (p = 0.099, 0.250, respectively), whereas the region 
containing amino acids 19-24 was not greater than the control protein (p = 0.255; Figure 3.7).  
The ability of the region containing amino acids 13-18 was significantly lower than that of the 
control protein (p = 0.002; Figure 3.7).  To confirm the data obtained through the simple binding 








Figure 3.6 Binding of BasTM 7-12 mutants to MCT2.  The ability of each amino acid to contribute 
to binding to MCT2 was evaluated through an in vitro binding assay, and compared to that of the 
BasTM 7-12 sequence, which was set to 100% binding.  Mutants with binding greater than 100% 
are thought to inhibit the interaction with MCT2, whereas those with binding less than 100% are 
thought to be involved in the interaction.  *=p<0.05 when individually compared to BasTM 7-12 












Figure 3.7 Binding of BasTM truncation mutants to MCT4. The ability of each section of the 
transmembrane domain of Basigin (BasTM 1-6, BasTM 7-12, BasTM 13-18, BasTM 19-24) to 
bind to MCT4 was assessed through an in vitro binding assay.  The binding of each BasTM mutant 
protein was individually compared to that of the BasTM-all protein using a paired, one-tailed T-









Table 3.3 Binding affinity of BasTM-all and the Bas-TM truncation mutants for MCT4 in M.  










BasTM 1-6 1.76±0.433 M 0.185
BasTM 7-12 2.03±0.14 M 0.015
BasTM 13-18 0.838±0.280 M 0.032
BasTM 19-24 2.44±0.12 M 0.012
BasTM-all-E13G 1.69±0.127 M 0.043
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(Table 3.3).  The affinity for MCT4 of the region containing BasTM 1-6 (1.76±0.433 M) was 
similar to that of the entire domain (BasTM-all; 1.36 ±0.19 M).  The affinities for MCT4 of the 
regions containing BasTM 7-12 (2.03±0.14 M) and BasTM 19-24 (2.44±0.12 M) were 
significantly lower than that of BasTM-all.  Surprisingly, the affinity for MCT4 of the region 
containing BasTM 13-18 was significantly greater than that of BasTM-all (0.838±0.280; p = 
0.032).  These data suggest that amino acids within the first six residues of the domain may play 
a role in binding to MCT4, but amino acids within residues 13-18 play a more significant role in 
the interaction.  The glutamate residue within the transmembrane domain of Basigin gene 
products is found at position 13.  The role of this amino acid was tested using the recombinant 
version of the entire Basigin transmembrane domain, in which the amino acid glutamate was 
mutated to glycine (BasTM-all-E13G), in an affinity binding assay (Figure 3.8).  The affinity of 
the BasTM-all-E13G protein for MCT4 was determined to be 1.69 ± 0.127 M, which is 
statistically greater than the affinity of the wild-type sequence for the transporter (p = 0.043; 
Table 3.3).  These data suggest that the glutamate plays a direct role in the interaction between 
Basigin and MCT4. 
To determine which amino acids in the segment containing amino acids 1-6 are used in 
the interaction with MCT4, deletion mutants in which individual amino acids were mutated to 
glycine were used.  Binding of each mutant was compared to that of the BasTM 1-6 protein 
(Figure 3.9).  It was determined that the protein containing an alanine-to-glycine mutation at 
position 3 (p = 0.046) had significantly lower binding to MCT4 than the BasTM 1-6 protein.  
This amino acid likely binds to MCT4.  The proteins containing a methionine-to-glycine 
mutation at position 1 (p = 0.009), an alanine-to-glycine mutation at position 2 (p = 0.041), a 











Figure 3.8 Binding curve of BasTM-all-E13G for MCT4. The absorbance obtained for 10 M was 
set to 100% binding, and the other absorbances were compared to it.  A logarithmic trendline was 












Figure 3.9 Binding of BasTM 1-6 mutants to MCT4. The ability of each amino acid to contribute 
to binding to MCT4 was evaluated through an in vitro binding assay, and compared to that of the 
BasTM 1-6 sequence, which was set to 100% binding.  Mutants with binding greater than 100% 
are thought to inhibit the interaction with MCT4, whereas those with binding less than 100% are 
thought to be involved in the interaction.  *=p<0.05 when individually compared to BasTM 1-6 





position 6 (p = 0.008) had significantly greater binding to MCT4 than the BasTM 1-6 protein.  
These amino acids are likely inhibitory in the interaction with MCT4. 
To determine which amino acids in the segment containing amino acids 13-18 are used in 
the interaction with MCT4, deletion mutants in which individual amino acids were mutated to 
glycine were again used.  Binding of each mutant was compared to that of the BasTM 13-18 
protein (Figure 3.10).  It was determined that the protein containing a glutamate-to-glycine 
mutation at position 13 (p = 0.022) had significantly lower binding to MCT4 than the BasTM 13-
18 protein.  This amino acid likely binds to MCT4.  The proteins containing a leucine-to-glycine 
mutation at position 15 (p = 0.010), a valine-to-glycine mutation at position 16 (p = 0.002), a 
leucine-to-glycine mutation at position 17 (p = 0.002), and a valine-to-glycine mutation at 
position 18 (p = 0.004) had significantly greater binding to MCT4 than the BasTM 13-18 
protein.  These amino acids are likely inhibitory in the interaction with MCT4. 
 
Assessing the expression of Basigin and MCT2 in vivo 
 To assess the biological relevance of the ability of Basigin to bind to MCT2, 
immunohistochemical analyses were conducted.  Paraffin-embedded sections of mouse retina 
were subjected to immunohistochemical analyses using antibodies specific for Basigin and 
MCT2 (Figure 3.11).  While Basigin is found on the Muller cells, photoreceptor cells, and blood 
vessels of the retina, MCT2 expression predominates in the inner and outer plexiform layers, 
where synapses between neurons form.  A more recent study by this laboratory investigated the 
expression of Basigin gene products within the mouse tongue (Figure 3.12). Basigin and MCT2 







Figure 3.10 Binding of BasTM 13-18 mutants to MCT4.  The ability of each amino acid to 
contribute to binding to MCT4 was evaluated through an in vitro binding assay, and compared to 
that of the BasTM 13-18 sequence, which was set to 100% binding.  Mutants with binding greater 
than 100% are thought to inhibit the interaction with MCT4, whereas those with binding less than 
100% are thought to be involved in the interaction.  *=p<0.05 when individually compared to 














Figure 3.11. Expression of Basigin and MCT2 in the mouse retina.  In both panels, the green 
fluorescence represents protein expression (Basigin or MCT2) and the blue fluorescence 
represents DRAQ5, which binds DNA.  The magnification bar represents 50 m.  Abbreviations: 
RPE, retinal pigmented epithelium; ONL, outer nuclear layer; OPL, outer plexiform layer; INL, 









Figure 3.12 Expression of Basigin and MCT2 in mouse tongue.  In the left panel, Basigin 
expression is represented by red fluorescence.  In the right panel, MCT2 expression is 
represented by green fluorescence.  In both panels, DRAQ 5 binding to DNA is represented by 













It is generally accepted that the proton-linked monocarboxylate transporters MCT1, 
MCT2, and MCT4 require an interaction with a cell adhesion molecule of the Basigin subset of 
the IgSF for expression at the plasma membrane and transport as an accessory protein to express 
at the plasma membrane (Kirk et al., 2000; Philp et al., 2003; Wilson et al., 2009).  It was 
thought that Basigin gene products interact with MCT1 and MCT4 (Kirk et al., 2000; Philp et al., 
2003), whereas the Neuroplastins interact with MCT2 (Wilson et al., 2013).  Little is known of 
Embigin, but it was shown to interact with MCT1 (Wilson et al., 2009).  The purpose of the 
present study was to characterize the interaction between Basigin gene products and MCT4, to 
determine if that interaction is like that for MCT1.  During the investigation, it was determined 
that the interactions of Basigin gene products with MCT1 and MCT4 are quite distinct from each 
other.  Additionally, although it was designed to serve as a negative control, an interaction 
between Basigin gene products and MCT2 was identified.  That interaction differs from those of 
the other two transporters.  In all, the data suggest that Basigin gene products, especially Basigin 
variant-1, which is ubiquitously expressed, are highly versatile proteins.   
While simple binding studies are useful in establishing interactions between proteins, 
affinity binding assays allow the interaction to be quantified and compared.  Initially, 
interactions between the transmembrane domain of Basigin and MCT1 were used as a positive 
control and to validate the study system used.  Affinity data for the Basigin-MCT1 interaction 
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obtained through this study was similar to those of previous studies and suggest that the 
interaction is of moderate affinity (Howard et al., 2010).  This study demonstrated that the 
affinity of Basigin for MCT2 and for MCT4 were statistically similar to that of MCT1.  This is 
the first study to indicate that Basigin can interact with MCT2, which was previously thought to 
interact solely with the Neuroplastins (Beesley et al., 2014).  The moderate affinity for MCT4 is 
not surprising considering a recent study in which an interaction between Basigin and MCT4 was 
determined to be crucial for development of glioblastoma and disruption of that interaction can 
reverse that development (Voss et al., 2017).   
The interactions between Basigin and monocarboxylate transporters are distinct.  A 
previous study in which the interaction between the transmembrane domain of Basigin gene 
products and MCT1 was investigated indicated that hydrophobic amino acids on both “ends” of 
the domain were used (Finch et al., 2009).  In the present study, it was determined that the 
interaction between Basigin and MCT2 utilizes two of the three amino acids at the extracellular-
facing portion of the membrane-spanning domain that are used by MCT1.  However, no amino 
acids within the cytoplasmic-facing portion of the membrane-spanning domain are used.  In 
contrast, it was determined that for the interaction with MCT4, Basigin uses only one amino acid 
within the extracellular-facing portion of the membrane-spanning domain used for the 
interactions with MCT1 and MCT2, but also uses the glutamate residue positioned at the center 
of the domain.  A summary of the interactions is shown in Figure 4.1. 
 One exciting component of the present study was the finding that the glutamate residue 
within the transmembrane domain of Basigin is used in the interaction with MCT4.  In previous 







Figure 4.1. Summary of Basigin binding to monocarboxylate transporters.  The transmembrane 
domain is depicted with the one-letter code for the individual amino acids shown in the circles.  
Amino acids within white circles are not used to bind any MCT.  Amino acids within blue circles 
are used by MCT1 only.  Amino acids within red circles are used by MCT4 only.  Amino acids 
within green circles are used by MCT1 and MCT2.  Amino acids within yellow circles are used 
by MCT1, MCT2, and MCT4.  
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must have a specific function within the hydrophobic domain of Basigin, and that the function 
was for the purposes of chaperoning MCT1 to the cell surface (Kirk et al., 2000).  That 
hypothesis was not supported by data from a previous study by this laboratory (Finch et al., 
2009).  However, the role of the glutamate was never determined.  In the present study, it was 
determined through two independent assays that glutamate interacts with MCT4.  When the 
residue was mutated to glycine within a recombinant protein consisting of the entire BasTM 
domain (BasTM-E13G), the affinity of the protein for MCT4 was statistically lower than that of 
the original BasTM protein. In addition, the simple binding assay using deletion mutants 
consisting of BasTM 13-18 showed that mutation of glutamate to glycine produced significantly 
decreased binding to MCT4 when compared to the original BasTM 13-18 sequence. A recent 
study using glioblastoma stem cells indicated that the interaction between Basigin and MCT4 
can be disrupted by acriflavine (Voss et al., 2017).  The acriflavine molecule binds to the 
extracellular domain of Basigin, as determined by surface plasmon resonance, and can prohibit 
proliferation of the glioblastoma cells (Voss et al., 2017).  Even more impressively, disruption of 
the Basigin-MCT4 interaction in mice with glioblastoma xenographs, showed significant 
inhibition of tumor progression in both early and late stages of the disease (Voss et al., 2017).  
The data presented herein suggest that the interaction between acriflavine and Basigin creates 
either a conformational change in the Basigin molecule that prevents the glutamate from 
interacting with MCT4 or changes the charge on the glutamate residue within Basigin and hence 
prevents an interaction with MCT4. 
 Another exciting finding from this study is the fact that Basigin binds to MCT2.  Previous 
studies in which the expression of MCTs in the absence of Basigin gene expression was 
investigated indicated that expression of MCT1 and MCT4 were altered in the absence of 
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Basigin, whereas the expression of MCT2 was unaffected (Philp et al., 2003).  The 
immunohistochemical analyses presented in this study provide an explanation for that 
observation.  Basigin and MCT2 are not expressed in the same places within the retina. 
Therefore, Basigin does not affect MCT2 expression in that tissue.  The immunohistochemical 
analyses of mouse tongue suggest that Basigin and MCT2 expression do overlap in that organ 
and provide biological relevance to the biochemical data obtained.  Unfortunately, an analysis of 
MCT2 expression in the mouse tongue in the absence of Basigin expression is beyond the 
current abilities of the laboratory and cannot be undertaken.  The laboratory has not been able to 
produce a Basigin-null animal in several years.   
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